Literature DB >> 28966418

Evaluating Utility Measurement from Recurrent Marker Processes in the Presence of Competing Terminal Events.

Yifei Sun1, Mei-Cheng Wang2.   

Abstract

In follow-up studies, utility marker measurements are usually collected upon the occurrence of recurrent events until a terminal event such as death takes place. In this article, we define the recurrent marker process to characterize utility accumulation over time. For example, with medical cost and repeated hospitalizations being treated as marker and recurrent events respectively, the recurrent marker process is the trajectory of cumulative cost, which stops to increase after death. In many applications, competing risks arise as subjects are at risk of more than one mutually exclusive terminal event, such as death from different causes, and modeling the recurrent marker process for each failure type is often of interest. However, censoring creates challenges in the methodological development, because for censored subjects, both failure type and recurrent marker process after censoring are unobserved. To circumvent this problem, we propose a nonparametric framework for recurrent marker process with competing terminal events. In the presence of competing risks, we start with an estimator by using marker information from uncensored subjects. As a result, the estimator can be inefficient under heavy censoring. To improve efficiency, we propose a second estimator by combining the first estimator with auxiliary information from the estimate under non-competing risks model. The large sample properties and optimality of the second estimator is established. Simulation studies and an application to the SEER-Medicare linked data are presented to illustrate the proposed methods. Supplemental materials are available online.

Entities:  

Keywords:  Competing risks; Cumulative incidence function; Marked recurrent events; Nonparametric estimation

Year:  2017        PMID: 28966418      PMCID: PMC5619681          DOI: 10.1080/01621459.2016.1166113

Source DB:  PubMed          Journal:  J Am Stat Assoc        ISSN: 0162-1459            Impact factor:   5.033


  18 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors:  H Zhao; L Tian
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

3.  Proportional means regression for censored medical costs.

Authors:  D Y Lin
Journal:  Biometrics       Date:  2000-09       Impact factor: 2.571

4.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

5.  Semiparametric analysis of correlated recurrent and terminal events.

Authors:  Yining Ye; John D Kalbfleisch; Douglas E Schaubel
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

6.  Joint Modeling and Estimation for Recurrent Event Processes and Failure Time Data.

Authors:  Chiung-Yu Huang; Mei-Cheng Wang
Journal:  J Am Stat Assoc       Date:  2004-12       Impact factor: 5.033

7.  Marginal analysis of recurrent events and a terminating event.

Authors:  R J Cook; J F Lawless
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

8.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

9.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

10.  PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS.

Authors:  Yanqing Sun; Peter B Gilbert; Ian W McKeague
Journal:  Ann Stat       Date:  2009-02-01       Impact factor: 4.028

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.